DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg tablets qd × 7 days) on the PK of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male and female subjects.
Healthy
DRUG: Treatment A (rosuvastatin)|DRUG: Treatment B (LX4211)|DRUG: Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
AUC, Day 1-Day 5, Day 13-Day 17
# of Adverse Events, Day 1-Day 17
This study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple-dose LX4211 400 mg (2 × 200-mg tablets qd × 7 days) on the PK of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male and female subjects.